MedPath

Exploring the Potential of Finger Prick Blood for Assessment of BIOmarkers for LOw Grade Inflammation and CVD Risk

Completed
Conditions
Biomarker
Registration Number
NCT04996589
Lead Sponsor
Wageningen University and Research
Brief Summary

There are currently no minimally invasive techniques for the measurement of lipopolysaccharide (LPS) and Apo-B48 that can be used in samples collected in field settings. In this project we want to explore whether postprandial assessment of biomarkers LPS and ApoB48 in blood withdrawn with a finger prick test can be used as marker for low grade inflammation and risk factor for CVD.

The primary objectives of this pilot study are to a) determine whether postprandial LPS and ApoB48 levels can be assessed in finger prick blood of both lean subjects and obese subjects; and b) compare postprandial LPS and ApoB48 levels assessed in venous blood and blood collected through a finger prick test.

This study is an observational pilot study in which postprandial LPS and ApoB48 will be assessed before and after ingestion of a high fat load in 5 lean and 5 obese subjects in the age range 18-70 years.

Samples will be collected under fasting conditions and in response to a high fat challenge test (1, 2, 4 and 6 hours post ingestion).

The risks for participation are very small if not negligible. No adverse effects of the high fat challenge were reported previously. Consumption of high amounts of saturated fat may cause some GI discomfort. Blood sampling will be performed via a cannula and the insertion can be a painful and may cause a bruise. Finger prick might also give a short pain sensation and small bruises. The amount of blood that is drawn from participants is relatively small (total 37.5 ml) and is therefore within acceptable limits. There are no direct benefits for the participants. In the BIOLOGIC study we include both lean subjects and obese subjects as we expect differences in postprandial responses related to differences in chylomicron production and LPS levels. Therefore it is important to explore these biomarkers in both target groups. This study can therefore be regarded as group-related, non-therapeutic research.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • Age 18-70 years
  • Living in the surroundings of Wageningen (max. 25 km)
  • Stable body weight for past 6 months
  • Suitable veins for insertion of cannula
  • BMI 18.5-22 kg/m2 (lean subjects)
  • BMI ≥ 30 kg/m2 (obese subjects)
Exclusion Criteria
  • Use of cholesterol-lowering medication (e.g. statins)
  • Use of diabetes medication (e.g. insulin, metformin)
  • Use of antibiotics or anti-inflammatory medication (e.g. NSAIDS such as ibuprofen)
  • Known allergy for any of the food components used in the study (milk, cream, sugars)
  • Blood clotting disorders
  • Current smokers
  • Alcohol consumption of > 21 units per week
  • Participation in another clinical trial at the same time
  • Being an employee of Wageningen Food & Biobased Research

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
LPS1-21 hour post ingestion

Serum levels LPS finger prick blood after high-fat shake intake

LPS_B2Baseline

Serum levels LPS finger prick blood under fasting conditions

LPS_B1Baseline

Serum levels LPS venous blood samples under fasting conditions

ApoB48_B1Baseline

Serum levels ApoB48 venous blood samples under fasting conditions

LPS1-11 hour post ingestion

Serum levels LPS venous blood samples after high-fat shake intake

ApoB48_B2Baseline

Serum levels ApoB48finger prick blood under fasting conditions

ApoB48_1-11 hour post ingestion

Serum levels ApoB48 venous blood samples after high-fat shake intake

LPS2-22 hours post ingestion

Serum levels LPS finger prick blood after high-fat shake intake

ApoB48_2-22 hours post ingestion

Serum levels ApoB48 finger prick blood after high-fat shake intake

LPS4-14 hours post ingestion

Serum levels LPS venous blood samples after high-fat shake intake

ApoB48_1-21 hour post ingestion

Serum levels ApoB48 finger prick blood after high-fat shake intake

LPS2-12 hours post ingestion

Serum levels LPS venous blood samples after high-fat shake intake

ApoB48_2-12 hours post ingestion

Serum levels ApoB48 venous blood samples after high-fat shake intake

ApoB48_4-14 hours post ingestion

Serum levels ApoB48 venous blood samples after high-fat shake intake

ApoB48_4-24 hours post ingestion

Serum levels ApoB48 finger prick blood after high-fat shake intake

LPS6-26 hours post ingestion

Serum levels LPS finger prick blood after high-fat shake intake

ApoB48_6-26 hours post ingestion

Serum levels ApoB48 finger prick blood after high-fat shake intake

LPS4-24 hours post ingestion

Serum levels LPS finger prick blood after high-fat shake intake

LPS6-16 hours post ingestion

Serum levels LPS venous blood samples after high-fat shake intake

ApoB48_6-16 hours post ingestion

Serum levels ApoB48 venous blood samples after high-fat shake intake

Secondary Outcome Measures
NameTimeMethod
LBP_44 hours post ingestion

Plasma LBP levels in venous blood samples after high-fat shake intake

LBP_11 hour post ingestion

Plasma LBP levels in venous blood samples after high-fat shake intake

LBP_22 hours post ingestion

Plasma LBP levels in venous blood samples after high-fat shake intake

LBP_BBaseline

Plasma LBP levels in venous blood samples collected under fasting conditions

sCD14_BBaseline

Plasma sCD14 levels in venous blood samples collected under fasting conditions

sCD14_11 hour post ingestion

Plasma sCD14 levels in venous blood samples after high-fat shake intake

LBP_66 hours post ingestion

Plasma LBP levels in venous blood samples after high-fat shake intake

sCD14_22 hours post ingestion

Plasma sCD14 levels in venous blood samples after high-fat shake intake

sCD14_66 hours post ingestion

Plasma sCD14 levels in venous blood samples after high-fat shake intake

sCD14_44 hours post ingestion

Plasma sCD14 levels in venous blood samples after high-fat shake intake

Trial Locations

Locations (1)

Stichting Wageningen Research

🇳🇱

Wageningen, Gelderland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath